-
Jefferies Sees Limited Impact To Gilead From Regulus' HCV Candidate's Clinical Hold
Tuesday, June 28, 2016 - 4:27pm | 214Read More...Shares of Regulus Therapeutics Inc (NASDAQ: RGLS) were down almost 48 percent on Tuesday, after the company said Monday the FDA had placed its lead product candidate, RG-101 – for the treatment of hepatitis C virus infection, on clinical hold. Following the news, Jefferies analysts...
-
Here's Why Regulus Therapeutics Gained 20%
Wednesday, February 17, 2016 - 1:09pm | 252Read More...Shares of Regulus Therapeutics Inc (NASDAQ: RGLS) were trading higher by nearly 20 percent late Wednesday morning after the company announced interim results from an ongoing Phase 2 study. Regulus Therapeutics' Phase 2 study of RG-101 for the treatment of Hepatitis C Virus infection (HCV) was...
